Trial Profile
Therapy of tumors SSTR2 expressing using somatostatine analogs labeled with 90Y and 177 Lu.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2011
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Yttrium-90-DOTATOC
- Indications Neuroendocrine tumours
- Focus Pharmacogenomic; Therapeutic Use
- 29 Jun 2011 New trial record